Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.102,00
0,34%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immuneering Corporation (IMRX) Immuneering Corporation (IMRX) Notizie

Immuneering Corporation

IMRX
1,58
0,02 (1,28%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/4/202418:00GLOBEIMM-1-104 is Synergistic with Chemotherapy in Pancreatic..
03/4/202422:05GLOBEImmuneering to Participate in the 23rd Annual Needham..
27/3/202413:00GLOBEImmuneering Announces First Patient Dosed in its Phase 1/2a..
14/3/202412:00GLOBEImmuneering Announces Positive Topline Results from Phase 1..
12/3/202413:00GLOBEImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of..
11/3/202413:00GLOBEImmuneering Doses First Patient in Phase 2a Clinical Trial..
05/3/202423:00GLOBEImmuneering to Present Preclinical Data on Universal-RAS..
04/3/202414:00GLOBEImmuneering to Participate in the Cowen 44th Annual Health..
01/3/202414:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202414:00GLOBEImmuneering Reports Fourth Quarter and Full Year 2023..
01/3/202413:58EDGAR2Form 8-K - Current report
20/2/202414:00GLOBEImmuneering Receives FDA Fast Track Designation for..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:15EDGAR2Form 8-K - Current report
16/1/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/1/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202314:00GLOBEImmuneering Announces FDA Clearance of IND Application for..
20/11/202322:05GLOBEImmuneering to Present at the 35th Annual Piper Sandler..
09/11/202322:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:05GLOBEImmuneering Reports Third Quarter 2023 Financial Results and..
12/10/202322:05GLOBEImmuneering Presents Preclinical Data Demonstrating..
04/10/202322:05GLOBEImmuneering to Present Preclinical Data on IMM-1-104 and..
06/9/202314:00GLOBEImmuneering to Present at the Morgan Stanley Healthcare..
03/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:05GLOBEImmuneering Reports Second Quarter 2023 Financial Results..
03/8/202322:04EDGAR2Form 8-K - Current report
05/6/202314:00GLOBEImmuneering Completes Dose Escalation in the IMM-1-104 Phase..
30/5/202314:00GLOBEImmuneering to Present at the Jefferies Healthcare..
Apertura: 1,73 Min: 1,60 Max: 1,73
Chiusura: 1,56

La tua Cronologia

NASDAQ
IMRX
Immuneering
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network